saRNA-LNP Platform for Sustained CAR Expression

Online Inquiry

Background Service What We Can Offer Workflow Highlights FAQs Contact

Despite the clinical success of CAR-T therapies, durable antitumor activity remains constrained by transient transgene expression, genotoxic risks associated with integrating vectors, and the high manufacturing costs of ex vivo cell engineering. Our saRNA-LNP platform addresses these limitations by enabling sustained, non-integrative CAR expression through a fully synthetic, repeat-dose–compatible delivery system. We offer a comprehensive service from saRNA construct design and LNP formulation to in vivo functional validation. Our solution ensures prolonged CAR surface presentation, reduced immunogenicity, and flexible redosing, empowering you with off-the-shelf, cost-effective tools for next-generation cell immunotherapy development.

Introduction

Self-amplifying RNA (saRNA) encapsulated in lipid nanoparticles (LNPs) represents a next-generation nucleic acid delivery platform that enables prolonged, high-level transgene expression with substantially reduced dosing frequency compared to conventional mRNA. saRNA-LNP provides a compelling alternative to viral vectors and transient mRNA electroporation by sustaining chimeric antigen receptor expression over extended periods, thereby enhancing cytotoxic persistence, reducing T cell exhaustion, and potentially improving long-term therapeutic outcomes in adoptive cell transfer regimens.

Fig.1 Profiling of saRNA lipid nanoparticle formulations. (OA Literature) Fig.1 Analysis of saRNA lipid nanoparticle formulations. ¹

Our Service

Our proprietary saRNA-LNP Platform for Sustained CAR Expression combines self-amplifying RNA with advanced lipid nanoparticles, enabling robust, multi-week CAR expression from a single, ultra-low dose without genomic integration risks. We provide biopharma partners with customizable, high-efficiency formulation and targeting solutions, significantly accelerating the development of safer, more cost-effective, and highly scalable ex vivo and in vivo CAR therapeutics.

What We Can Offer

Our platform offers integrated saRNA vector engineering from backbone selection and base modification to UTR/poly(A) optimization paired with comprehensive functional validation, enabling sustained, potent CAR expression and long-lasting anti-tumor activity.

Featured services of saRNA-LNP platform for sustained CAR expression at Creative Biolabs. (Creative Biolabs Original)

Our Service Process

Required Starting Materials:

saRNA Expression Vector Plasmid.
Lipid Components for LNP.

Key Steps:

Workflow of saRNA-LNP platform for sustained CAR expression at Creative Biolabs. (Creative Biolabs Original)

Final Deliverables:

saRNA-LNP Formulation.
Quality Control and Analytical Report.

Key Advantages

Prolonged Expression Duration: By leveraging viral non-structural proteins to drive self-replication within the host cytoplasm, the platform extends CAR protein expression from a few days to several weeks, thereby sustaining long-term anti-tumor efficacy.
Significant Dose-Sparing Effect: The self-amplifying nature of saRNA allows a minimal initial dose to achieve or exceed standard expression thresholds, substantially reducing manufacturing costs and raw material burdens.
Advanced Multigenic Co-expression and Logic Gating: The platform utilizes internal ribosome entry sites or subgenic promoters to precisely co-express multiple proteins from a single RNA strand, facilitating the programmatic design of dual-targeted CAR logic gates to overcome tumor heterogeneity and mitigate off-target toxicities.

FAQ

Q1: How does the saRNA-LNP platform achieve sustained CAR expression compared to conventional mRNA?

A1: Conventional mRNA degrades rapidly, leading to transient CAR expression. Our saRNA platform incorporates engineered viral non-structural protein genes. Once delivered into the cytoplasm via LNPs, these proteins form a replicase complex that continuously amplifies the CAR-encoding RNA template, extending CAR expression from days to several weeks.

Q2: Are there any genomic integration risks associated with the saRNA platform?

A2: No. The entire self-amplification and translation process occurs strictly within the host cell cytoplasm. Unlike lentiviral or retroviral vectors, saRNA does not enter the nucleus and does not integrate into the host genome, eliminating the risk of insertional mutagenesis.

Why Choose Us?

Our cutting-edge saRNA-LNP platform redefines CAR cell therapy by delivering sustained, multi-week receptor expression alongside profound dose-sparing efficiency via autonomous cytoplasmic self-replication. By enabling precise multigenic co-expression and advanced logic gating without genomic integration risks, we provide an ultra-safe, highly scalable, and cost-effective solution tailored for next-generation oncology therapeutics.

Customer Reviews

"We were looking for a way to achieve the prolonged therapeutic window of viral CAR-T therapies without the associated insertional mutagenesis risks. This saRNA-LNP platform exceeded our expectations. The self-amplifying RNA sustained robust CAR expression in primary T cells for over two weeks from a single transfection, significantly outperforming standard mRNA." Dr. Alistair Vance.

"The synergy between their high-yield saRNA synthesis and optimized LNP encapsulation is outstanding. We utilized this service for in vivo CAR-T generation and observed exceptional spleen and lymph node targeting with minimal systemic toxicity. The LNP stability and uniform particle size meant we got highly reproducible CAR expression dynamics across all test cohorts." Dr. Elena Rostova.

How to contact us?

Looking to advance your adoptive immunotherapy pipeline? Engage our scientific team to integrate our proprietary self-amplifying RNA lipid nanoparticle technology into your CAR-based programs. Partner with us to access bespoke formulation services, schedule an in-depth feasibility assessment, and obtain a custom-tailored proposal designed around your preclinical or clinical benchmarks.

Reference

Blakney, Anna K et al. "Inside out: optimization of lipid nanoparticle formulations for exterior complexation and in vivo delivery of saRNA." Gene therapy vol. 26,9 (2019): 363-372. Distributed under Open Access License CC BY 4.0, without modification. https://doi.org/10.1038/s41434-019-0095-2.

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.